Metformin for weight loss in obese non-diabetic Nigerians
Official title: Effect of Metformin Use on Weight Loss in Obese, Non-diabetic People
Run by University Of Nigeria Teaching Hospital · NCT07297290 · Data updated 2026-11-12
This trial tests whether metformin helps adults in Nigeria who are obese but do not have diabetes lose weight.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 20 Years to 59 Years |
| Sex | All |
| Enrollment | 220 (estimated) |
| Sponsor | University Of Nigeria Teaching Hospital Research network |
| Locations | 2 sites (Enugu, Enugu State and 1 other locations) |
| Status | Recruiting |
| Started | July 23, 2025 |
| Main results expected | March 31, 2027 |
| Study ends | September 30, 2027 |
| Registry record updated | December 22, 2025 |
| Trial ID | NCT07297290 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults near Enugu with BMI ≥30 kg/m2, fasting plasma glucose <7.0 mmol/L, no weight-control medication use in the past 12 months, and not currently in another trial are ideal candidates.
✕Probably not a fit
People with diabetes (fasting plasma glucose ≥7.0 mmol/L), those already on weight-loss treatments, or those unable to attend the Enugu sites are unlikely to benefit from this participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a phase 3, randomized, double-blind, placebo-controlled trial enrolling Black Nigerian adults with obesity (BMI ≥30 kg/m2) and fasting plasma glucose below 7.0 mmol/L. Participants will be randomly assigned to receive metformin or a matching placebo and followed over time to measure weight change, insulin resistance, and markers of cardiovascular risk. The study excludes people who have used medical treatment for weight control in the previous 12 months or who are currently enrolled in another clinical trial. All study activities take place at the University of Nigeria Teaching Hospital and an associated pathology facility in Enugu.
Why it matters
Potential benefit: If effective, metformin could offer an affordable, widely available way to help obese non-diabetic Nigerians lose weight and reduce cardiometabolic risk.
How similar studies have gone: Previous trials in high-income countries have shown modest weight loss with metformin in obese patients, but this effect has not yet been demonstrated in Black African populations.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * • Obesity (defined as body mass index ≥ 30kg/m2), * Fasting plasma glucose (\<7.0mmol/L) * No medical treatment for weight control in the previous 12 months * No participation in a current clinical trial Exclusion Criteria: * • Obesity (defined as body mass index ≥ 30kg/m2), * Fasting plasma glucose (\<7.0mmol/L) * No medical treatment for weight control in the previous 12 months * No participation in a current clinical trial
Where it's running
-
Pathology Facility
Enugu, Enugu State, Nigeria Recruiting -
University of Nigeria Teaching Hospital
Enugu, Enugu State, Nigeria Recruiting
Study contacts
- Principal investigator: Ifeyinwa D Nnakenyi, Md — University Of Nigeria Teaching Hospital
- Study coordinator: Chiamaka C Onu, BSc
- Email: mowri2025@gmail.com
- Phone: +2347031800855
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Asprosin and miRNA Profiles in Young Women with Metabolic Syndrome
This study tests whether certain blood biomarkers, including asprosin and six microRNAs, differ between young women with metabolic syndrome and healthy peers.
-
Prenatal Exercise to See How Cardio or Strength Training Affects Blood Sugar
This study tests whether different types and amounts of exercise during pregnancy can improve blood sugar control in women with gestational diabetes.
-
Structured obesity care pathway with lifestyle support and GLP-1 therapy in Algeria
This study tests whether a structured, multidisciplinary obesity program plus optional GLP-1 therapy helps adults with obesity in Algeria lose weight and improve health compared with usual care.
-
Alpelisib Challenge Test to measure insulin secretory capacity
Researchers will test a new approach to measure how much insulin the body can produce in people at various weights and with or without insulin resistance, using alpelisib around a meal test.
-
Inositol and Metformin with Mediterranean or Low-Carb Diets in Women with PCOS
This trial tests whether adding inositol, metformin, or folic acid to either a Mediterranean or a low-carbohydrate diet helps women with PCOS and insulin resistance lose weight and improve metabolic markers.
-
Inulin Prebiotic for Perimenopausal Women with Overweight or Obesity
This study tests whether 2 weeks of inulin can affect gut and vaginal microbes, heart health, and muscle health in perimenopausal women who are overweight or obese, using a crossover design.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.